Martyn Irvine has said he is very much looking forward to getting stuck into his new role with Cycling Ireland following ...

The milestone achievement places NMC Royal Hospital DIP among a select group of only 229 hospitals worldwide to earn this ...

General Abdullah announces an exciting lineup of over 67 key EGF events set to take place across the UAE for the 2024-2025 ...

Revolution Medicines (RVMD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami ...

Discover Cardiff Oncology's promising results with Onvansertib for RAS-mutated colorectal cancer, potentially leading to ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

According to DelveInsight’s analysis, the growth of the KRAS Inhibitors market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, and robust pipeline ...

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

Ras Al Khaimah, United Arab Emirates: Ras Al Khaimah Tourism Development Authority (RAKTDA) has been named a winner for the ...

Barclays analyst Peter Lawson maintained a Buy rating on Revolution Medicines (RVMD – Research Report) today and set a price target of ...

Expert Rev Anticancer Ther. 2009;9(4):511-523. As the name implies, mTOR is inhibited by rapamycin. Rapamycin (also known as Sirolimus or Rapamune ®) is a macrocyclic lactone antibiotic that was ...

Hereditary changes in genes are often the cause of rare diseases. For example, disease-causing gene variants (PVs) in the ...